Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lyell Immunopharma, Inc. - Common Stock (NQ:LYEL)

13.55 -0.05 (-0.37%)
Streaming Delayed Price Updated: 12:32 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lyell Immunopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Here are the top movers in Thursday's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
What's going on in today's session ↗
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
What's going on in today's session ↗
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy ↗
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities. 
Via Benzinga
News headline image
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in September Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
LYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q2 2024 ↗
LYEL stock results show that Lyell Immunopharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
3 Biotech Stocks to Sell in August Before They Crash & Burn ↗
Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.